(Q36054857)

11 August 2017

1 reference

title

Cyclophosphamide in lupus nephritis. (English)

1 reference

11 August 2017

F A Houssiau

1

1 reference

11 August 2017

publication date

1 January 2005

1 reference

11 August 2017

1 reference

11 August 2017

volume

14

1 reference

11 August 2017

issue

1

1 reference

11 August 2017

page(s)

53-58

1 reference

Treatment of Diffuse Proliferative Lupus Nephritis with Prednisone and Combined Prednisone and Cyclophosphamide

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2060OA

Wegener's Granulomatosis: Prospective Clinical and Therapeutic Experience With 85 Patients for 21 Years

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2060OA

Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2060OA

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2060OA

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2060OA

Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2060OA

Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2060OA

Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2060OA

Short course of weekly low-dose intravenous pulse cyclophosphamide in the treatment of lupus nephritis: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2060OA

Short term effects of intravenous pulses of cyclophosphamide in the treatment of connective tissue disease crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2060OA

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2060OA

Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2060OA

High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2060OA

Sequential therapies for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2060OA

An open study of B lymphocyte depletion in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2060OA

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2060OA

Treatment of murine lupus with CTLA4Ig

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2060OA

10.1191/0961203305LU2060OA

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference